Cover Image
市場調查報告書

軸性脊椎關節炎:開發中產品分析

Axial Spondyloarthritis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361636
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
Back to Top
軸性脊椎關節炎:開發中產品分析 Axial Spondyloarthritis - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 111 Pages
簡介

軸性脊椎關節炎,是脊椎和薦腸關節相關發炎性關節炎之一,HLA-B27遺傳基因的存在有很強的關聯性。HLA-B27用遺傳基因檢驗有效。

本報告提供軸性脊椎關節炎治療藥的開發情形的相關調查,開發中產品的概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等。

簡介

  • 調查範圍

軸性脊椎關節炎概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發軸性脊椎關節炎治療藥的企業

  • AstraZeneca Plc
  • Eli Lilly and Company
  • Johnson & Johnson
  • Novartis AG
  • Panacea Biotec Ltd
  • Sandoz International GmbH
  • Sun Pharma Advanced Research Company Ltd
  • UCB SA

藥物簡介

暫停中的計劃

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9365IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H1 2017, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.

Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axial Spondyloarthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical and Unknown stages are 2, 6, 1, 2 and 1 respectively.

Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Axial Spondyloarthritis - Overview
    • Axial Spondyloarthritis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Axial Spondyloarthritis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Axial Spondyloarthritis - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Eli Lilly and Company
    • Johnson & Johnson
    • Novartis AG
    • Panacea Biotec Ltd
    • Sandoz International GmbH
    • Sun Pharma Advanced Research Company Ltd
    • UCB SA
  • Axial Spondyloarthritis - Drug Profiles
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brodalumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • certolizumab pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ixekizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • secukinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tildrakizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ustekinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Axial Spondyloarthritis - Dormant Projects
  • Axial Spondyloarthritis - Product Development Milestones
    • Featured News & Press Releases
      • Apr 24, 2017: Kyowa Hakko Kirin Announces Initiation of Global Phase 3 Study of KHK4827 (Brodalumab) in Patients with Axial Spondyloarthritis (axSpA)
      • Apr 21, 2017: Sandoz Receives CHMP Positive Opinion For Erelzi
      • Mar 06, 2017: First CIMZIA Study of Its Kind Showed Minimal to No Transfer of Drug from Mother's Plasma to Breast Milk
      • Nov 11, 2016: UCB Presents Data on Cimzia (certolizumab pegol) at 2016 ACR/ARHP Annual Meeting
      • Oct 25, 2016: Certolizumab pegol (Cimzia) AutoClicks Prefilled Pen - a New Self-injection Device Designed in Collaboration With Patients and Good Grips - is Now Available in the UK on the NHS
      • Jun 08, 2016: UCB commitment to addressing real world patient needs on display at the Annual European Congress of Rheumatology (EULAR 2016)
      • Nov 06, 2015: UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting
      • Nov 14, 2014: UCB Shows Strong Scientific Presence On Certolizumab pegol (CIMZIA) At Leading Rheumatology Meeting
      • Sep 20, 2013: UCB receives CHMP positive opinion for Cimzia in severe active axial spondyloarthritis
      • Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis
      • Jun 14, 2013: UCB's Certolizumab Pegol Rapidly Improves Pain, Fatigue And Physical Function In axSpA Patients In Phase III Study
      • Feb 20, 2013: UCB Announces Regulatory Filings For Cimzia To Treat Psoriatic Arthritis And Axial Spondyloarthritis
      • Nov 13, 2012: UCB Announces Presentation Of Phase III Trial Results Of Certolizumab Pegol In Axial Spondyloarthritis At ACR 2012 Annual Meeting
      • Nov 09, 2012: UCB To Present New Data On Certolizumab Pegol At ACR's 2012 Annual Scientific Meeting
      • Apr 16, 2012: UCB Announces Positive Top-Line Phase III Results Of Cimzia In Axial Spondyloarthritis And Ankylosing Spondylitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Axial Spondyloarthritis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Axial Spondyloarthritis - Pipeline by AstraZeneca Plc, H1 2017
  • Axial Spondyloarthritis - Pipeline by Eli Lilly and Company, H1 2017
  • Axial Spondyloarthritis - Pipeline by Johnson & Johnson, H1 2017
  • Axial Spondyloarthritis - Pipeline by Novartis AG, H1 2017
  • Axial Spondyloarthritis - Pipeline by Panacea Biotec Ltd, H1 2017
  • Axial Spondyloarthritis - Pipeline by Sandoz International GmbH, H1 2017
  • Axial Spondyloarthritis - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Axial Spondyloarthritis - Pipeline by UCB SA, H1 2017
  • Axial Spondyloarthritis - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Axial Spondyloarthritis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top